Tuesday, Nov. 3 election losses leave mifepristone's pending review among several vital pro-life battlegrounds, as we face a pro-abortion Congress.
Tuesday, Nov. 3 election losses leave mifepristone's pending review among several vital pro-life battlegrounds, as we face a pro-abortion Congress.
End of DispatchRead Original Coverage on foxnews
